Frazier Life Sciences β Full Portfolio
166 tracked investments Β· listed companies and verified rows first
AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders.
BiotechSan Diego, US
Robert Hoffman(Executive Officer)Carol Gallagher(Director)Marco Londei(Executive Officer)John Schmid(Director)Nicholas Lydon(Director)Hamza Suria(Executive Officer, Director)
Board seatJames N. TopperΒ· per SEC Form D
BiotechWestlake Village, US
Alexander Asam(Director)Ricky Sun(Director)Jonathan Silverstein(Director)Todd Franklin Watanabe(Executive Officer, Director)
Board seatPatrick HeronDaniel EstesΒ· per SEC Form D Β· $94.5M raise Β· filed Oct 2019
BiotechCanton, US
Gino Santini(Director)Eran Nadav(Director)John Freund(Director)Garen Bohlin(Director)David Hirsch(Director)Michael Heffernan(Executive Officer, Director)
Board seatPatrick HeronΒ· per SEC Form D
BiotechCarmel, US
Timothy Knickerbocker(Executive Officer, Director)Richard DiMarchi(Executive Officer, Director)Peter Kent Hawryluk(Executive Officer, Director)
Board seatPatrick HeronΒ· per SEC Form D Β· $115.2M raise Β· filed Nov 2022
Rare liver disease treatment company.
San Diego, US
Board seatPatrick HeronPatrick J. HeronPatrick HeronΒ· per SEC Form D Β· $68.5M raise Β· filed Jan 2026
Passage Bio is a company focused on developing treatments for central nervous system (CNS) diseases, with an emphasis on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
Carl Gordon(Director)Tadataka Yamada(Executive Officer, Director, Promoter)Saqib Islam(Director)Thomas Street Address 1 Woiwode(Director)Stephen Squinto(Executive Officer, Director)
Board seatPatrick HeronΒ· per SEC Form D
BiotechSouth San Francisco, US
Tracy Saxton(Director)Grant E Pickering(Executive Officer, Director, Promoter)Jeff Fairman(Executive Officer)Ashish Khanna(Executive Officer)William Newell(Director)Patrick Enright(Director)
Board seatPatrick HeronΒ· per SEC Form D Β· $110M raise Β· filed Apr 2020
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)Jonathan E. Lim, M.D.(President and Executive Chairman)Gary Yeung, CFA(Chief Business Officer)Alexander W. Casdin(Director)James A. Bristol, Ph.D.(Director)
Maze Therapeutics develops precision medicines for kidney disease and other conditions with large unmet medical needs, using a genetic variant-based approach through its Compass platform.
BiotechMedical Devices
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
BiotechPalo Alto, US
Henry Ji(Executive Officer, Director)Stephen Ma(Executive Officer, Director)Jaisim Shah(Executive Officer, Director)David Lemus(Director)
BoardYue Alexander Wu(Director)Jay Chun(Director)
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.
BiotechHealthtechNew Haven, US
Edward Mathers(Director)Michael Heffernan(Director)Lisa Delfini(Executive Officer)James Cassella(Director)Dominick Colangelo(Director)Jennifer L. Good(Executive Officer, Director)
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)Sanford Madigan(Co-Founder, President & Chief Business Officer)Analeah Heidt(Chief Scientific Officer)
Board seatJames TopperΒ· per SEC Form D
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)Mark Bachleda(Executive Officer, Director)Robert Vitti(Executive Officer)Oliver Stauch(Executive Officer)Oliver Boris Stauch(Executive Officer)Conrad Wang(Director)
Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.
BiotechHealthtechMedical DevicesMassachusetts, US
Daniel Orlando(Chief Executive Officer)Jeremy Lack(Director)Stephen Krauss(Director)Tasos Konidaris(Executive Officer)James Topper(Director)Steve Dubin(Director)
Board seatJames N. TopperΒ· per SEC Form D
BiotechWaltham, US
Chris Pacheco(Director)Carlos Loya(Executive Officer, Director)
Board seatLauren MifflinΒ· per SEC Form D Β· $1.2M raise Β· filed Mar 2022
BiotechNewton, US
Axel Bolte(Director)James Topper(Director)Alexey Margolin(Executive Officer, Director)Gino Santini(Director)Louis Brenner(Executive Officer)Stephen Kraus(Director)
Board seatJames N. TopperΒ· per SEC Form D Β· $53M raise Β· filed Dec 2015
South San Francisco, US
Board seatJames TopperJames W. BrushΒ· per SEC Form D
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Liam Ratcliffe(Director)Ashish Khanna(Secretary & Chief Business Officer)Terry P. Gould(Director)Wilbur H. Gantz III(Director)
Board seatJames N. TopperΒ· per SEC Form D
BiotechAnn Arbor, US
Carol Gallagher(Director)Randall Whitcomb(Director)James Topper(Director)Julia C. Owens(Executive Officer, Director)William Harrington(Director)
Board seatJames N. TopperΒ· per SEC Form D Β· $59.1M raise Β· filed Dec 2017
HealthtechPhoenix, US
ARASH ARAGHI(Executive Officer, Director)DAVID JACOFSKY(Executive Officer, Director)PETER SLATE(Executive Officer)JOHN BROWN(Director)WARREN COHEN(Director)BRYAN WALL(Executive Officer, Director)
Board seatNathan EveryΒ· per SEC Form D Β· $14M raise Β· filed Dec 2016
BiotechCleveland, US
Kevin Lalande(Director)Howard Dittrich(Executive Officer)Robert Baltera, Jr.(Executive Officer, Director)Jerel Davis(Director)James Topper(Director)
Board seatJames N. TopperΒ· per SEC Form D Β· $31.9M raise Β· filed Feb 2015
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Steve Elms(Director)Dan Burgess(Director)Ted Schroeder(Director)Kevin Forrest(Executive Officer)Dirk Thye(Executive Officer)
Board seatPatrick HeronΒ· per SEC Form D
HealthtechLong Beach, US
Keith Arnold(Executive Officer)Richard Whitney(Director)DAVID KOSLOFF(Director)Rob Mahan(Executive Officer)Jim Adams(Executive Officer)Vera Appleyard(Executive Officer)
Board seatNader NainiΒ· per SEC Form D Β· $14.4M raise Β· filed Nov 2015
HealthtechSan Carlos, US
Alan Sachs(Director)Laura G. Eichorn(Executive Officer)Dennis Henner(Director)Hugh Y. Rienhoff(Executive Officer, Director)
Board seatPatrick HeronPatrick HeronΒ· per SEC Form D Β· $80M raise Β· filed Nov 2020
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Brenton K. Ahrens(Director)Michael W. Dunne(Executive Officer, Promoter)Ronald M. Hunt(Director)Mark Chin(Director)Corey N. Fishman(Executive Officer, Director, Promoter)Robert Hopfner(Director)
Board seatPatrick J. HeronΒ· per SEC Form D Β· $2.8M raise Β· filed Jul 2020
BiotechHamilton
Brenton K. Ahrens(Director)James I. Healy(Director)Mark Chin(Director)Patrick J. Heron(Director)Ronald M. Hunt(Director)Shahzad Malik(Director)
Board seatPatrick HeronΒ· per SEC Form D Β· $51.6M raise Β· filed Jan 2020
BiotechKing Of Prussia, US
James Topper(Director)Colin Goddard(Director)Markus Goebel(Director)Brian MacDonald(Executive Officer, Director)Remy Sukhija(Executive Officer)Jeffrey Bird(Director)
Board seatJames N. TopperΒ· per SEC Form D Β· $17.1M raise Β· filed Apr 2016
Bellevue, US
Kelly Allison(Executive Officer)Scott Svenson(Executive Officer, Director, Promoter)
Board seatNader NainiΒ· per SEC Form D Β· $35M raise Β· filed Mar 2016
Menlo Park, US
Yigong Ge(Director)Chen Yu(Director)Brent Ahrens(Director)David Socks(Executive Officer, Director, Promoter)
Board seatPatrick HeronΒ· per SEC Form D Β· $21.3M raise Β· filed Jun 2015
Seattle, US
Hendrik Struik(Executive Officer, Director, Promoter)George Willett(Executive Officer, Promoter)Nader Naini(Director, Promoter)Kenneth Hanover(Director, Promoter)Joe Whitters(Director, Promoter)Ben Magnano(Director, Promoter)
Board seatNader NainiΒ· per SEC Form D Β· $32.3M raise Β· filed Jul 2017
Belmont, US
Board seatNathan EveryΒ· per SEC Form D Β· $46M raise Β· filed Jul 2016
South San Francisco, US
Board seatMaria FardisΒ· per SEC Form D Β· $89.1M raise Β· filed Jun 2026
Seattle, US
Gregory R Roer(Executive Officer, Director)
Board seatNader NainiΒ· per SEC Form D Β· $53M raise Β· filed Oct 2018
BiotechMenlo Park, US
Yigong Ge(Executive Officer, Director)Michael Savino(Executive Officer)David Socks(Director)
Board seatPatrick HeronΒ· per SEC Form D Β· $10.7M raise Β· filed Jul 2018
Early-stage company from the Archer Seed Fund that received follow-on funding in outside-led rounds.
Philadelphia, US
Mark Hefferman(Executive Officer, Director)Tadataka Yamada(Director)Nancy Hong(Director)
BoardCindy Cole(Director)
Board seatPatrick HeronAditya KohliΒ· per SEC Form D
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.
BiotechHealthtechGermantown, US
Gi-Hyeok Yang(Director)Carole Welsch(Executive Officer)William L. Rust(Executive Officer, Director, Promoter)Roy Arup(Director)Bernie Treidl(Director)
Board seatJames N. TopperΒ· per SEC Form D Β· $40M raise Β· filed Feb 2021
BiotechSan Diego, US
Cam Garner(Treasurer)Theodore R. Schroeder(President and Chief Executive Officer)Cam Gallagher(Secretary)
Board seatPatrick HeronΒ· per SEC Form D Β· $45.7M raise Β· filed Apr 2016
BiotechGreenwood Village, US
Frank Segrave(President)Michael Beckloff(Chief Development Officer)Robert Mauro(Chief Operating Officer)Bhaskar Chaundhuri(Director)Nathan Every(Director)Barry Barnard(Chief Financial Officer)
Board seatPatrick HeronNathan EveryΒ· per SEC Form D Β· $4.6M raise Β· filed Oct 2015
Vernon Hills, US
Robin Selati(Director)Barry Allen(Director)Jonathan Stevens(Executive Officer)Donna Zarcone(Director)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtech
BiotechRedwood City, US
C. David Nicholson(Director)Linda Rubinstein(Executive Officer)Rabia Gurses Ozden(Director)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)Soo Hong(Director)
PartnerDaniel EstesΒ· led
PartnerJames N. TopperΒ· led
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical Devices
BiotechSeattle, US
Dr. Mitchell H Gold(Executive Officer, Director)Michael Kornacker(Executive Officer, Director)Ryan Swanson(Executive Officer, Director)David Miller(Executive Officer, Director)Jay Venkatesan(Director)James Paul Rickey(Senior Vice President and Chief Financial Officer)
PartnerJames N. TopperΒ· led
Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a global rare disease biotechnology company that develops medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)Craig A. Wheeler(Director)Ted W. Love(Director)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)Margaret G. McGlynn(Director)
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
AndrΓ©s Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
Attovia develops precision biologics using its ATTOBODY platform for patients with immune-mediated diseases.
BiotechDigital Health
BiotechLa Jolla, US
Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)Michael Martin PhD.(Director)
BoardTodd Brady(Director)
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical Devices
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)Dajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Bluejay is a biotechnology company focused on therapeutic development.
Biotech
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
PartnerPatrick HeronΒ· led
Seattle and Singapore-based biotech developing next-generation multi-payload antibody-drug conjugates for cancer treatment.
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease).
BiotechHealthtech
Graham Heap(President, Research and Development)Ezequiel Neimark(Head of Clinical Development)Taylor Spector(Head of Medical Affairs)Scott Stirn(Head of CMC)
PartnerPatrick HeronΒ· led
Received FDA approval for TEMBEXA (brincidofovir) to treat smallpox.
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical Devices
PartnerPatrick HeronΒ· led
Complete Pharmacy Solutions (CPS) is a long-term care pharmacy that fills new admissions, new orders, and routine refills for health care centers, integrating with PointClickCare and other software for electronic ordering.
Digital HealthHealthtech
Received FDA approval for Tracleer to treat pulmonary arterial hypertension.
PartnerJames N. TopperΒ· led
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)
BiotechWaltham, US
Michael Ross(Director)Oliver Rosen, M.D.(Executive Officer)Thomas Kelly(Executive Officer)John Martin(Director)Daniel F. Flynn, Ph.D.(Executive Officer)Liam Ratcliffe, M.D., Ph.D.(Director)
BiotechEmeryville, US
Andrew Allen(Executive Officer, Director)Shefali Agarwal(Director)Lawrence Corey(Director)Vassiliki Economides(Executive Officer)Steve Krognes(Director)Matthew Hawryluk(Executive Officer)
Halda provides AI-powered agents for student recruitment and enrollment management at educational institutions.
AI & Machine LearningEdTechSaaSProvo, US
Lance Hydrick(Executive Officer, Director)Dallin Palmer(Director)
BoardSid Krommenhoek(Director)
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)Leyi Wang(Manager)Rebecca Frey(Manager)
BoardTim Shannon(Manager)Liam Ratcliffe(Manager)
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Hummingbird Bioscience develops antibody-based therapeutics, including antibody-drug conjugates (ADCs), using proprietary linker-payload and biologics discovery platforms.
BiotechHealthtech
PartnerDaniel EstesΒ· led
BiotechSan Diego, US
Valerie Harding, Ph.D.(Senior Vice President, Chemistry, Manufacturing and Controls)Bernard Parker(Chief Commercial Officer)Zachary Hornby(Chief Operating Officer)Igor P. Bilinsky, Ph.D.(Executive Officer)Matt Onaitis, J.D.(Secretary and General Counsel)Robert Wild, Ph.D.(Chief Scientific Officer and SVP, Research)
PartnerPatrick HeronΒ· led
PartnerJames N. TopperΒ· led
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
BiotechHealthtechMedical Devices
Chuhan Chung(Chief Medical Officer)
Iolyx Therapeutics develops targeted immunomodulatory therapeutics for ocular inflammatory diseases at the intersection of immunology and ophthalmology, addressing conditions affecting both the front of the eye (such as dry eye, ocular allergies, and uveitis) and the back of the eye (such as age-related macular degeneration and diabetic retinopathy).
BiotechMedical Devices
Elizabeth Jeffords(CEO & President)Erin Newman(Chief Development Officer)Shannon Dahl(Chief Scientific Officer)Bryan Boyle(Chief Legal & Administrative Officer)
Krystal Biotech develops and commercializes redosable gene therapies to treat severe, rare, and life-threatening diseases with limited or no approved treatments.
BiotechMedical DevicesPittsburgh, US
Doug Norby(Director)Dino Rossi(Director)Suma M. Krishnan(Director)Krish S. Krishnan(Executive Officer, Director)
BoardDan Janney(Director)
BiotechMenlo Park, US
Daniel Estes, Ph.D.(President)Tracy Saxton, Ph.D.(Director)Helen Jenkins(Chief Executive Officer)Roger Ulrich, Ph.D.(Director)Steve Bailey(Vice President)Anna Chen(Treasurer and Secretary)
PartnerPatrick HeronΒ· led
PartnerJames N. TopperΒ· led
BiotechDublin 1
Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)
NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.
BiotechHealthtechMedical Devices
OraPharma develops pharmaceutical products and tools for dental professionals to address oral health concerns, serving dental practices and patients.
HealthtechMedical DevicesBridgewater, US
Palvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform.
BiotechHealthtechWayne, US
Phathom Pharmaceuticals is a biopharmaceutical company developing and commercializing therapeutics for patients with acid-related gastrointestinal (GI) disorders.
BiotechHealthtech
PartnerJames N. TopperΒ· led
PartnerPatrick HeronΒ· led
Radionetics develops small molecule radiopharmaceuticals that target GPCRs, using radioisotope-tethered ligands to image and treat cancerous tumors as part of a theranostics precision medicine approach.
BiotechMedical DevicesSan Diego, US
BiotechMenlo Park, US
Brett Ewald(Executive Officer)Andrew Schwab(Director)Umesh Gangadharmath(Executive Officer)Dan Estes(Executive Officer, Director)Istvan Molnar(Executive Officer)Yunfei Zhu(Executive Officer)
Pharmaceutical company acquired by Biogen
PartnerJames N. TopperΒ· led
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.
BiotechHealthtech
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)
PartnerKevin LiΒ· led
Sidewinder Bio develops next-generation bispecific antibody-drug conjugates (ADCs) designed to treat solid tumors with enhanced specificity for difficult-to-treat cancers.
BiotechMedical Devices
A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
PartnerDaniel EstesΒ· led
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Fan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)Jeffrey Bluestone(Executive Officer, Director, Promoter)
South San Francisco, US
Germany-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, acquired by Gilead Sciences for $3.15 billion upfront plus up to $1.85 billion in contingent payments.
BiotechLondon
Jan-Anders Karlsson(Executive Officer, Director)David Ebsworth(Director)Patrick Humphrey(Director)Peter Spargo(Executive Officer)Ken Cunningham(Director)Kenneth Newman(Executive Officer)
SpringWorks is a biopharmaceutical company developing targeted oncology and rare disease therapies, including its gamma secretase inhibitor nirogacestat being evaluated in BCMA combination regimens for multiple myeloma.
BiotechHealthtech
ZEMDRI (plazomicin) is an aminoglycoside antibiotic injection indicated for adults with complicated urinary tract infections, including pyelonephritis, caused by certain susceptible microorganisms.
BiotechHealthtech
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.